453 Objectives Imaging of apoptosis may provide real time information on the biological
effect of anti-cancer treatment and may allow personalized treatment for individual patients …

Purpose Early assessment of tumor response to therapy is vital for treatment optimization for
the individual cancer patient. Induction of apoptosis is an early and nearly universal effect of …

[18F] ML-10 is a novel apoptosis radiotracer for positron emission tomography (PET). We
assess the apoptosis response of intracranial tumor early after CyberKnife (CK) treatment by …

Purpose: We investigated 2-(5-fluoro-pentyl)-2-methyl-malonic acid (18F-ML-10) positron
emission tomography (PET) imaging of apoptosis posttherapy to determine optimal timing …

The ability to assess tumor apoptotic response to therapy could provide a direct and prompt
measure of therapeutic efficacy. 18 F-labeled 2-(5-fluoro-pentyl)-2-methyl-malonic acid ([18 …

Objectives The authors present the first use of the novel positron emission tomography
(PET) apoptosis tracer 18F‐labeled 2‐(5‐fluoro‐pentyl)‐2‐methyl‐malonic acid (18F‐ML …

One of the current challenges in oncology is to develop imaging tools to early detect the
response to conventional chemotherapy and adjust treatment strategies when necessary …

Clinical PET of apoptosis may have substantial value in advancing patient care. We report
here the first-in-humans study with 18F-labeled 2-(5-fluoropentyl)-2-methyl malonic acid …

Clinical molecular imaging of apoptosis is a highly desirable yet unmet challenge. Here we
provide the first report on 18F-labeled 5-fluoropentyl-2-methyl-malonic acid (18F-ML-10), a …

Abstract Purpose [18 F] ML-10 is the most advanced radiopharmaceutical for the clinical
imaging of the apoptosis phenomenon by PET. The preparation of this radiopharmaceutical …